BACKGROUND: Atrial fibrillation is associated with substantial mortality and morbidity from
stroke and thromboembolism. Despite an efficacious oral anticoagulation therapy (warfarin) …

This chapter about antithrombotic therapy in atrial fibrillation (AF) is part of the Seventh
ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based …

ContextWarfarin has been shown to be highly efficacious for preventing thromboembolism in
atrial fibrillation in randomized trials, but its effectiveness and safety in clinical practice is …

This chapter about antithrombotic therapy in atrial fibrillation (AF) is part of the American
College of Chest Physicians Evidence-Based Guidelines Clinical Practice Guidelines (8th …

Background—Prediction of stroke and atrial fibrillation in healthy individuals is challenging.
We examined whether excessive supraventricular ectopic activity (ESVEA) correlates with …

Background For patients receiving therapy with oral anticoagulants (OACs), the proportion of
time spent in the therapeutic range (ie, anticoagulation control) is strongly associated with …

Background and Purpose—More than 2 million Americans have atrial fibrillation, and
without antithrombotic therapy, their stroke rate is increased 5-fold. In randomized controlled …

Vitamin K antagonists (VKAs) have been the mainstay of anticoagulation therapy for more
than 50 years. VKAs are mainly used for the prevention of stroke in patients with atrial …

Objectives To assess rates and determinants of treatment discontinuation of or changes in
initial antihypertensive drug therapy in a large cohort of patients from Lombardia (Italy) …

ContextStroke is a major cause of morbidity and mortality, and the application of evidence
for stroke prevention varies considerably. ObjectiveTo review the most recent, high-quality …